Time-dependent reversal of synaptic plasticity induced by physiological concentrations of oligomeric Aβ42: An early index of Alzheimer's disease

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Koppensteiner, Peter ^a,b,c   Trinchese, Fabrizio ^a,b   Fà, Mauro ^a,b   Puzzo, Daniela ^d   Gulisano, Walter ^d   Yan, Shijun ^a,b   Poussin, Arthur ^a,b   Liu, Shumin ^a,b   Orozco, Ian ^a,b   Dale, Elena ^a,b   Teich, Andrew F ^a,b   Palmeri, Agostino ^d   Ninan, Ipe ^e   Boehm, Stefan ^c   Arancio, Ottavio ^a,b  

^a Department of Medicine   (United States)

^b Medical University of Vienna ^*  (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF CATANIA   (Italy)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); GLUTAMATE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PEPTIDE FRAGMENT; SYNAPSIN; SYNAPTOPHYSIN; SYP PROTEIN, MOUSE;

ALZHEIMER DISEASE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HIPPOCAMPUS; HUMAN; MEMORY DISORDER; METABOLISM; MOUSE; NERVE CELL; NERVE CELL PLASTICITY; NERVE ENDING; NEWBORN; PATCH CLAMP TECHNIQUE; PATHOLOGY; PATHOPHYSIOLOGY; PRIMARY CELL CULTURE; PROTEIN MULTIMERIZATION; SYNAPSE; SYNAPTIC TRANSMISSION; TIME FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMANS; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; NEURONAL PLASTICITY; NEURONS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PATCH-CLAMP TECHNIQUES; PEPTIDE FRAGMENTS; PRESYNAPTIC TERMINALS; PRIMARY CELL CULTURE; PROTEIN MULTIMERIZATION; RECEPTORS, GLUTAMATE; SYNAPSES; SYNAPSINS; SYNAPTIC TRANSMISSION; SYNAPTOPHYSIN; TIME FACTORS;

EID: 84986236319     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep32553     Document Type: Article

References (73)

1. Selkoe, D. J. Alzheimer's disease is a synaptic failure. Science 298, 789-791, doi: 10.1126/science.1074069 (2002).
2. Reitz, C. Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis 2012, 369808, doi: 10.1155/2012/369808 (2012).
3. Herrup, K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci 18, 794-799, doi: 10.1038/nn.4017 (2015).
4. Castello, M. A., Jeppson, J. D. & Soriano, S. Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease. BMC Neurol 14, 169, doi: 10.1186/s12883-014-0169-0 (2014).
5. Puzzo, D., Gulisano, W., Arancio, O. & Palmeri, A. The keystone of Alzheimer pathogenesis might be sought in A physiology. Neuroscience 307, 26-36 (2015).
6. Terry, R. D. et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580, doi: 10.1002/ana.410300410 (1991).
7. Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T. & Hyman, B. T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639 (1992).
8. Dickson, D. W. et al. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16, 285-298; discussion 298-304 (1995).
9. Sloane, J. A. et al. Lack of correlation between plaque burden and cognition in the aged monkey. Acta Neuropathol 94, 471-478 (1997).
10. Katzman, R. et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 23, 138-144, doi: 10.1002/ana.410230206 (1988).
11. Delaere, P. et al. Large amounts of neocortical beta A4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person. Neurosci Lett 116, 87-93 (1990).
12. Wallace, W. C. et al. Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. Brain Res Mol Brain Res 10, 173-178 (1991).
13. Gentleman, S. M., Nash, M. J., Sweeting, C. J., Graham, D. I. & Roberts, G. W. Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. Neurosci Lett 160, 139-144 (1993).
14. McKenzie, J. E., Gentleman, S. M., Roberts, G. W., Graham, D. I. & Royston, M. C. Increased numbers of beta APP-immunoreactive neurones in the entorhinal cortex after head injury. Neuroreport 6, 161-164 (1994).
15. Roberts, G. W. et al. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 57, 419-425 (1994).
16. Torack, R. M. & Miller, J. W. Immunoreactive changes resulting from dopaminergic denervation of the dentate gyrus of the rat hippocampal formation. Neurosci Lett 169, 9-12 (1994).
17. Xia, D. et al. Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer's disease. Neuron 85, 967-981, doi: 10.1016/j.neuron.2015.02.010 (2015).
18. Regland, B. & Gottfries, C. G. The role of amyloid beta-protein in Alzheimer's disease. Lancet 340, 467-469 (1992).
19. Trinchese, F. et al. Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J Clin Invest 118, 2796-2807, doi: 10.1172/JCI34254 (2008).
20. Fa, M. et al. Novel Selective Calpain 1 Inhibitors as Potential Therapeutics in Alzheimer's Disease. J Alzheimers Dis 49, 707-721, doi: 10.3233/JAD-150618 (2015).
21. Viola, K. L. & Klein, W. L. Amyloid beta oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol 129, 183-206, doi: 10.1007/s00401-015-1386-3 (2015).
22. Kamenetz, F. et al. APP processing and synaptic function. Neuron 37, 925-937 (2003).
23. Cirrito, J. R. et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48, 913-922, doi: 10.1016/j. neuron.2005.10.028 (2005).
24. Puzzo, D. et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28, 14537-14545, doi: 10.1523/JNEUROSCI.2692-08.2008 (2008).
25. Morley, J. E. et al. A physiological role for amyloid-beta protein:enhancement of learning and memory. J Alzheimers Dis 19, 441-449, doi: 10.3233/JAD-2009-1230 (2010).
26. Lawrence, J. L. et al. Regulation of presynaptic Ca2+, synaptic plasticity and contextual fear conditioning by a N-terminal betaamyloid fragment. J Neurosci 34, 14210-14218, doi: 10.1523/JNEUROSCI.0326-14.2014 (2014).
27. Mastrangelo, P. et al. Dissociated phenotypes in presenilin transgenic mice define functionally distinct gamma-secretases. Proc Natl Acad Sci USA 102, 8972-8977, doi: 10.1073/pnas.0500940102 (2005).
28. Giedraitis, V. et al. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett 427, 127-131, doi: 10.1016/j.neulet.2007.09.023 (2007).
29. Puzzo, D. et al. Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 69, 819-830, doi: 10.1002/ana.22313 (2011).
30. Garcia-Osta, A. & Alberini, C. M. Amyloid beta mediates memory formation. Learn Mem 16, 267-272, doi: 10.1101/lm.1310209 (2009).
31. Caccamo, A., Oddo, S., Sugarman, M. C., Akbari, Y. & LaFerla, F. M. Age-and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 26, 645-654, doi: 10.1016/j.neurobiolaging.2004.06.013 (2005).
32. Iwata, N., Takaki, Y., Fukami, S., Tsubuki, S. & Saido, T. C. Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res 70, 493-500, doi: 10.1002/jnr.10390 (2002).
33. Yasojima, K., Akiyama, H., McGeer, E. G. & McGeer, P. L. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett 297, 97-100 (2001).
34. Yasojima, K., McGeer, E. G. & McGeer, P. L. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res 919, 115-121 (2001).
35. Ninan, I. & Arancio, O. Presynaptic CaMKII is necessary for synaptic plasticity in cultured hippocampal neurons. Neuron 42, 129-141 (2004).
36. Malgaroli, A. & Tsien, R. W. Glutamate-induced long-term potentiation of the frequency of miniature synaptic currents in cultured hippocampal neurons. Nature 357, 134-139, doi: 10.1038/357134a0 (1992).
37. Arancio, O., Kandel, E. R. & Hawkins, R. D. Activity-dependent long-term enhancement of transmitter release by presynaptic 3,5-cyclic GMP in cultured hippocampal neurons. Nature 376, 74-80, doi: 10.1038/376074a0 (1995).
38. Antonova, I. et al. Rapid increase in clusters of presynaptic proteins at onset of long-lasting potentiation. Science 294, 1547-1550, doi: 10.1126/science.1066273 (2001).
39. Luscher, C., Nicoll, R. A., Malenka, R. C. & Muller, D. Synaptic plasticity and dynamic modulation of the postsynaptic membrane. Nat Neurosci 3, 545-550, doi: 10.1038/75714 (2000).
40. Carroll, R. C., Lissin, D. V., von Zastrow, M., Nicoll, R. A. & Malenka, R. C. Rapid redistribution of glutamate receptors contributes to long-term depression in hippocampal cultures. Nat Neurosci 2, 454-460, doi: 10.1038/8123 (1999).
41. Lissin, D. V., Carroll, R. C., Nicoll, R. A., Malenka, R. C. & von Zastrow, M. Rapid, activation-induced redistribution of ionotropic glutamate receptors in cultured hippocampal neurons. J Neurosci 19, 1263-1272 (1999).
42. Shi, S. H. et al. Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Science 284, 1811-1816 (1999).
43. Pickard, L. et al. Transient synaptic activation of NMDA receptors leads to the insertion of native AMPA receptors at hippocampal neuronal plasma membranes. Neuropharmacology 41, 700-713 (2001).
44. Lu, W. et al. Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron 29, 243-254 (2001).
45. Rodriguez, O. C. et al. Conserved microtubule-actin interactions in cell movement and morphogenesis. Nat Cell Biol 5, 599-609, doi: 10.1038/ncb0703-599 (2003).
46. Furukawa, K. & Mattson, M. P. Cytochalasins Protect Hippocampal Neurons Against Amyloid Peptide Toxicity: Evidence that Actin Depolymerization Suppresses Ca2+ Influx. Journal of neurochemistry 65, 1061-1068 (1995).
47. Huot, J., Houle, F., Marceau, F. & Landry, J. Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Circ Res 80, 383-392 (1997).
48. Roy, S. M. et al. Targeting human central nervous system protein kinases: An isoform selective p38alphaMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models. ACS Chem Neurosci 6, 666-680, doi: 10.1021/acschemneuro.5b00002 (2015).
49. Watterson, D. M. et al. Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. PLoS One 8, e66226, doi: 10.1371/journal.pone.0066226 (2013).
50. Wang, Q., Walsh, D. M., Rowan, M. J., Selkoe, D. J. & Anwyl, R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24, 3370-3378, doi: 10.1523/JNEUROSCI.1633-03.2004 (2004).
51. Origlia, N. et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci 28, 3521-3530, doi: 10.1523/JNEUROSCI.0204-08.2008 (2008).
52. Lee, J. C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746, doi: 10.1038/372739a0 (1994).
53. Selcher, J. C. et al. A role for ERK MAP kinase in physiologic temporal integration in hippocampal area CA1. Learn Mem 10, 26-39, doi: 10.1101/lm.51103 (2003).
54. Roberson, E. D. et al. The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA1 of hippocampus. J Neurosci 19, 4337-4348 (1999).
55. Krucker, T., Siggins, G. R. & Halpain, S. Dynamic actin filaments are required for stable long-term potentiation (LTP) in area CA1 of the hippocampus. Proc Natl Acad Sci USA 97, 6856-6861, doi: 10.1073/pnas.100139797 (2000).
56. Bliss, T. V. & Collingridge, G. L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361, 31-39, doi: 10.1038/361031a0 (1993).
57. Phillips, R. G. & LeDoux, J. E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106, 274-285 (1992).
58. Abramov, E. et al. Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 12, 1567-1576, doi: 10.1038/nn.2433 (2009).
59. Lambert, T. J., Storm, D. R. & Sullivan, J. M. MicroRNA132 modulates short-term synaptic plasticity but not basal release probability in hippocampal neurons. PLoS One 5, e15182, doi: 10.1371/journal.pone.0015182 (2010).
60. Zucker, R. S. & Regehr, W. G. Short-term synaptic plasticity. Annu Rev Physiol 64, 355-405, doi: 10.1146/annurev. physiol.64.092501.114547 (2002).
61. Minamide, L. S., Striegl, A. M., Boyle, J. A., Meberg, P. J. & Bamburg, J. R. Neurodegenerative stimuli induce persistent ADF/cofilinactin rods that disrupt distal neurite function. Nature Cell Biology 2, 628-636 (2000).
62. Song, C., Perides, G., Wang, D. & Liu, Y. F.-Amyloid peptide induces formation of actin stress fibers through p38 mitogenactivated protein kinase. J Neurochem 83, 828-836, doi: 10.1046/j.1471-4159.2002.01182.x (2002).
63. Zhang, C., Qiu, H. E., Krafft, G. A. & Klein, W. L. Protein kinase C and F-actin are essential for stimulation of neuronal FAK tyrosine phosphorylation by G-proteins and amyloid beta protein. FEBS Lett 386, 185-188 (1996).
64. Mungarro-Menchaca, X., Ferrera, P., Moran, J. & Arias, C. beta-Amyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine. J Neurosci Res 68, 89-96 (2002).
65. Liu, S. et al. alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J 23, 4506-4516, doi: 10.1038/sj.emboj.7600451 (2004).
66. Dineley, K. T., Jahrling, J. B. & Denner, L. Insulin resistance in Alzheimer's disease. Neurobiol Dis 72 Pt A, 92-103, doi: 10.1016/j. nbd.2014.09.001 (2014).
67. Tampellini, D. et al. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abetarelated synaptic alterations. J Neurosci 29, 9704-9713, doi: 10.1523/JNEUROSCI.2292-09.2009 (2009).
68. Choi, D. W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1, 623-634 (1988).
69. Masliah, E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol 10, 509-519 (1995).
70. Orozco, I. J., Koppensteiner, P., Ninan, I. & Arancio, O. The schizophrenia susceptibility gene DTNBP1 modulates AMPAR synaptic transmission and plasticity in the hippocampus of juvenile DBA/2J mice. Mol Cell Neurosci 58, 76-84, doi: 10.1016/j. mcn.2013.12.003 (2014).
71. Fa, M. et al. Preparation of oligomeric beta-amyloid 1-42 and induction of synaptic plasticity impairment on hippocampal slices. J Vis Exp, doi: 10.3791/1884 (2010).
72. Koppensteiner, P., Boehm, S. & Arancio, O. Electrophysiological profiles of induced neurons converted directly from adult human fibroblasts indicate incomplete neuronal conversion. Cell Reprogram 16, 439-446, doi: 10.1089/cell.2014.0054 (2014).
73. Puzzo, D. et al. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci 25, 6887-6897, doi: 10.1523/JNEUROSCI.5291-04.2005 (2005).